Previous 10 | Next 10 |
MediWound (NASDAQ:MDWD) announces positive initial data from seven of the maximum fifteen patients in its ongoing Phase 2 pharmacology study of EscharEx, the company’s next-generation enzymatic debridement agent under development for chronic and hard-to-heal wounds. Shares up 2.5%...
Data Demonstrate EscharEx Reduces Biofilm and Bacterial Burden EscharEx is Shown to be Safe with No Observed Safety Issues YAVNE, Israel, Dec. 20, 2021 (GLOBE NEWSWIRE) -- MediWound Ltd. (Nasdaq: MDWD) (the “Company”), a fully-integrated biopharmaceutical company...
YAVNE, Israel, Dec. 06, 2021 (GLOBE NEWSWIRE) -- MediWound Ltd. (Nasdaq: MDWD) (the “Company”), a fully-integrated biopharmaceutical company focused on next-generation biotherapeutic solutions for tissue repair and regeneration, today announced it has completed patient enrollm...
YAVNE, Israel, Nov. 18, 2021 (GLOBE NEWSWIRE) -- MediWound Ltd. (Nasdaq: MDWD) (the “Company”), a fully-integrated biopharmaceutical company focused on next-generation biotherapeutic solutions for tissue repair and regeneration, today announced that the Company has received po...
MediWound Ltd. (MDWD) Q3 2021 Results Conference Call November 16, 2021 08:30 AM ET Company Participants Monique Kosse - LifeSci Advisors Sharon Malka - CEO Boaz Gur-Lavie - CFO Conference Call Participants Bryan Bergin - Cowen and Company Ryan Zimmerman - BTIG Kevin DeGeeter - Oppenheimer Sw...
MediWound (NASDAQ:MDWD): Q3 GAAP EPS of -$0.12 beats by $0.01. Revenue of $6.37M (-3.9% Y/Y) beats by $0.7M. Press Release For further details see: MediWound EPS beats by $0.01, beats on revenue
Third Quarter Revenues of $6.4 Million ; Year-to-Date 2021 Revenues Increased 21% C larity on R egulatory P athway for R esubmission of NexoBrid BLA , A nticipated in M id- 2022 Escha...
MediWound (NASDAQ:MDWD) is scheduled to announce Q3 earnings results on Tuesday, November 16th, before market open. The consensus EPS Estimate is -$0.13 (-85.7% Y/Y) and the consensus Revenue Estimate is $5.67M (-14.5% Y/Y). Over the last 3 months, EPS estimates have seen 2 upward revisions a...
AQUA, ARMK, OTCPK:AWLCF, CAN, CWCO, DAO, DAVA, DOYU, ECC, ESEA, FLNG, FUV, GDS, HD, HIVE, OTCQX:IMBBY, JMIA, LILM, MDWD, NTES, OCSL, OZON, REE, SE, TDG, OTCQX:TRSSF, VOD, OTCQX:VYGVF, WMT, ZEPP For Seeking Alpha's full earnings season calendar, click here. For further details see: ...
YAVNE, Israel, Nov. 04, 2021 (GLOBE NEWSWIRE) -- MediWound Ltd. (Nasdaq: MDWD), a fully integrated biopharmaceutical company focused on next-generation bio-therapeutic solutions for tissue repair and regeneration, today announced that the Company will release its financial results for the t...
News, Short Squeeze, Breakout and More Instantly...
Funds to be used for clinical development of EscharEx ® to treat diabetic foot ulcers (DFUs) Award advances MediWound’s DFU program and its future revenues four years ahead of original schedule YAVNE, Israel, July 16, 2024 (GLOBE NEWSWIRE) -- MediWound Ltd....
Mölnlycke® Health Care announces US $15m investment in next-generation enzymatic therapeutics company MediWound Ltd PR Newswire GOTHENBURG, Sweden , July 15, 2024 /PRNewswire/ -- Mölnlycke Health Care, a world-leading MedTech company specialising i...
YAVNE, Israel, July 15, 2024 (GLOBE NEWSWIRE) -- MediWound Ltd. (Nasdaq: MDWD), the world leader in next-generation enzymatic therapeutics for tissue repair, today announced it has entered into a definitive share purchase agreement with several new and existing investors, including Mölnlycke...